# IlDong Pharmaceutical Co Ltd clinical trials: 50 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 50 trials with IlDong Pharmaceutical Co Ltd as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by IlDong Pharmaceutical Co Ltd: 50 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/ildong-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 50
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 50, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 10, 2024 | NCT06635226 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects | IlDong Pharmaceutical Co Ltd | Phase 1 | Recruiting | Healthy Adult Subjects | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06635226) |
| October 2, 2023 | NCT06063291 | Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects | IlDong Pharmaceutical Co Ltd | Phase 1 | Completed | Healthy Adult Subjects | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06063291) |
| December 23, 2022 | NCT05663879 | Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of ID120040002 in Healthy Volunteers | IlDong Pharmaceutical Co Ltd | Phase 1 | Unknown | Healthy | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05663879) |
| November 3, 2022 | NCT05604287 | Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects | IlDong Pharmaceutical Co Ltd | Phase 1 | Terminated | Healthy Participants | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05604287) |
| February 28, 2022 | NCT05259020 | To Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy Adult Volunteers | IlDong Pharmaceutical Co Ltd | Phase 1 | Unknown | Dyslipidemias, Hypertension | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05259020) |
| July 29, 2021 | NCT04982705 | IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics | IlDong Pharmaceutical Co Ltd | Phase 1 | Unknown | Type 2 Diabetes | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04982705) |
| January 31, 2020 | NCT04249908 | Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal Function | IlDong Pharmaceutical Co Ltd | Phase 1 | Unknown | Renal Impairment | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04249908) |
| January 6, 2020 | NCT04218162 | Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean | IlDong Pharmaceutical Co Ltd | Phase 3 | Completed | Acute Migraine | 294 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04218162) |
| December 17, 2019 | NCT04202536 | Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate | IlDong Pharmaceutical Co Ltd | Phase 4 | Unknown | Hepatitis B, Besifovir Dipivoxil Maleate, Tenofovir Disoproxil Fumarate | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04202536) |
| December 4, 2019 | NCT04185090 | To Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety Between ID1801 and ID1803 in Healthy Male Adults | IlDong Pharmaceutical Co Ltd | Phase 1 | Unknown | Hypertension, Dyslipidemias | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04185090) |
| May 28, 2019 | NCT03964103 | qQ-lab Daily-IBS for Irritable Bowel Syndrome | IlDong Pharmaceutical Co Ltd | Not applicable | Completed | Irritable Bowel Syndrome (IBS) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03964103) |
| May 6, 2019 | NCT03937648 | Study to Evaluate Pharmacokinetics, Safety, and Tolerability Ildong COL-144 Tablet in Korean Healthy Volunteers | IlDong Pharmaceutical Co Ltd | Phase 1 | Unknown | Healthy | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03937648) |
| April 8, 2019 | NCT03907228 | Study to Evaluate the Use of RHT-3201 in SCORAD Reduction in Young Patients With Atopic Dermatitis | IlDong Pharmaceutical Co Ltd | Not applicable | Unknown | Dermatitis, Atopic | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03907228) |
| March 26, 2019 | NCT03889145 | A Study to Evaluate the Drug-drug Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide | IlDong Pharmaceutical Co Ltd | Phase 1 | Completed | Healthy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03889145) |
| March 22, 2019 | NCT03885778 | A Food Effect Study of Besifovir in Healthy Subjects | IlDong Pharmaceutical Co Ltd | Phase 4 | Completed | Food Effect, Health Subjects | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03885778) |
| December 3, 2018 | NCT03761082 | Post Marketing Surveillance of PIRESPA® TAB 200mg (Pirfenidone) for Evaluating the Safety and Efficacy | IlDong Pharmaceutical Co Ltd | Observational | Completed | Idiopathic Pulmonary Fibrosis | 258 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03761082) |
| November 15, 2018 | NCT03742544 | Post Marketing Surveillance of Telostop TAB (Telmisartan/Rosuvastatin) for Evaluating the Safety and Efficacy | IlDong Pharmaceutical Co Ltd | Observational | Unknown | Hypertension, Dyslipidemias | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03742544) |
| November 14, 2018 | NCT03741010 | Belviq Tablet® Post Marketing Surveillance Protocol | IlDong Pharmaceutical Co Ltd | Observational | Unknown | Weight Loss | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03741010) |
| August 31, 2018 | NCT03655288 | A Post-marketing Surveillance to Assess Safety and Efficacy of Twotopsplus. | IlDong Pharmaceutical Co Ltd | Observational | Unknown | Hypertension | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03655288) |
| August 27, 2018 | NCT03648801 | A Post-marketing Surveillance to Assess Safety and Efficacy of Telostop Plus Tab. | IlDong Pharmaceutical Co Ltd | Observational | Unknown | Hypertension, Dyslipidemia | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03648801) |
| August 27, 2018 | NCT03648788 | A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe | IlDong Pharmaceutical Co Ltd | Observational | Unknown | Mixed Dyslipidemia | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03648788) |
| August 22, 2018 | NCT03642340 | A Post-marketing Surveillance to Assess Safety and Efficacy of Besivo | IlDong Pharmaceutical Co Ltd | Observational | Unknown | Chronic Hepatitis b | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03642340) |
| July 27, 2018 | NCT03604016 | Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver | IlDong Pharmaceutical Co Ltd | Phase 4 | Unknown | Hepatitis B | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03604016) |
| June 25, 2018 | NCT03566316 | Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia | IlDong Pharmaceutical Co Ltd | Phase 3 | Completed | Hypertension With Hyperlipidemia | 134 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03566316) |
| December 6, 2017 | NCT03363269 | Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease | IlDong Pharmaceutical Co Ltd | Phase 2 | Completed | Alzheimer Disease | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03363269) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 24 |
| Phase 2 | 1 |
| Phase 3 | 13 |
| Phase 4 | 3 |
| Not applicable | 2 |
| Observational | 7 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 24 |
| Unknown | 22 |
| Terminated | 3 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hypertension | 8 |
| Hepatitis B, Chronic | 4 |
| Dyslipidemias | 4 |
| Hypercholesterolemia | 2 |
| Hepatitis B | 2 |
| Prostatic Hyperplasia | 2 |
| Neuralgia | 2 |
| Acute Coronary Syndrome | 2 |
| Renal Insufficiency | 1 |
| Erectile Dysfunction | 1 |
| Liver Cirrhosis | 1 |
| Alzheimer Disease | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Idiopathic Pulmonary Fibrosis | 1 |
| Hyperlipidemias | 1 |
| Dermatitis, Atopic | 1 |
| Weight Loss | 1 |
| Essential Hypertension | 1 |
| Irritable Bowel Syndrome | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [General dentistry practices in the United States](https://specstream.ai/data/businesses/general-dentistry-practices/united-states)
- [Welding companies in the United States](https://specstream.ai/data/businesses/welding-companies/united-states)
- [Jewelry and watches manufacturers in the United States](https://specstream.ai/data/businesses/jewelry-and-watches-manufacturers/united-states)
- [B2B quarry companies in the United States](https://specstream.ai/data/businesses/b2b-quarry-companies/united-states)
- [Ophthalmology practices in the United States](https://specstream.ai/data/businesses/ophthalmology-practices/united-states)
